PepSets™ Peptide Libraries ❭

PepSets™ can be supplied with a precise length and offset designed to best suit the user’s assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence to adapt the usage for any experimental purpose.

In recent years, PepSets™ have had tremendous successes in the immunology sector for vaccine and drug development. These versatile molecular tools have further applications in dozens of fields, including epitope mapping and structure-activity studies.  

  • Discover crucial residues with an Alanine Scan Library 
  • Map epitopes with an Overlapping Peptide Library 
  • Narrow down the shortest active sequences with a Truncated Peptide Library

Fast & Reliable

Mimotopes is the founder of peptide libraries. Across the 35 years since its inception, the technology and its userbase have developed side-by-side to make PepSets™ an unrivaled juggernaut in research today.

Hundreds of peptides are synthesized simultaneously with Mimotopes’ exclusive parallel synthesis technology. Thanks to a rapid production cycle, peptide libraries reach their users fast, aiming to never delay critical experiments.

Contact us today for a quote!

Australia

☎ +61 3 9565 1111
✉ australia@mimotopes.com

North and South America

☎ +1 651 603 0909
✉ useast@mimotopes.com
uswest@mimotopes.com

Asia

☎ +61 3 9565 1111
✉ asia@mimotopes.com

UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547
✉ europe@mimotopes.com

Go to article: Home | The GLP-1 drug shortage is over. What’s next for the compounders?Go to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: MilliporeSigmaGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: ZETAGo to article: In DepthGo to article: The GLP-1 drug shortage is over. What’s next for the compounders?Go to article: Big pharma faces headwinds in China as vaccine sales declineGo to article: How can pharma manage rising trial costs?Go to article: Can AI replace medical writers? Experts say not immediatelyGo to article: Saving shelved ultra-rare therapies through unorthodox fundingGo to article: Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts?Go to article: Weight loss implants to increase compliance and cut admin burden for patientsGo to article: Greens Company InsightGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Buyer's GuidesGo to article: Next issue